Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial
Authors: Pedro M Machado, Michael P McDermott, Thomas Blaettler, Claus Sundgreen, Anthony A Amato, Emma Ciafaloni, Miriam Freimer, Summer B Gibson, Sarah M Jones, Todd D Levine, Thomas E Lloyd, Tahseen Mozaffar, Aziz I Shaibani, Matthew Wicklund, Anders Rosholm, Tim Dehli Carstensen, Karen Bonefeld, Anders Nørkær Jørgensen, Karina Phonekeo, Andrew J Heim, Laura Herbelin, Richard J Barohn, Michael G Hanna, Mazen M Dimachkie, Mazen Dimachkie, Jeffrey Statland, Mamatha Pasnoor, Omar Jawdat, Andrew Heim, Ali Ciersdorff, Sandhya Sasidharan, Melissa Currence, Todd Levine, Rebecca Otutoa, Angelina Cooper, Tahseen Mozaffar, Ali Habib, Jonathan Cauchi, Shannon Ung, Veena Mathew, Isela Hernandez, Summer Gibson, Mark Bromberg, Kyle Mahoney, Crystal Neate, Teresa Janecki, Mike Papadakis, Miriam Freimer, MacKenzie Kaschalk, Sarah Heintzman, Matthew Wicklund, Brenna Baines, Alexa Vareldzis, Emily Hyslop, Brianna Blume, Emma Ciafaloni, Elizabeth Luebbe, Katy Eichinger, William Martens, Stephanie Gregory, Joanne Janciuras, Anthony Amato, Christopher Doughty, Kristen Roe, Patricia Flynn, Emily Russo, Thomas Lloyd, Jemima Albayda, Eleni Tiniakou, Simone Thomas, Sarah Jones, Guillermo Solorzano, Matthew Elliott, Ted Burns, Allison Crowell, Deborah Eggleston, Mary Wagoner, Aziz Shaibani, Chantae Oates, Pedro Machado, Michael Hanna, Linda Greensmith, Mhoriam Ahmed, Vinojini Vivekanandam, Matthew Appleby, George Ransley, Edwin Eshun Eshun, Iwona Skorupinska, Louise Germain, Ana Marie Laxa, Joana Roca Pontes, Anna Bellin, Dolapo Anifowoshe
Journal: The Lancet Neurology (2023)

Inclusion body myositis is the most common progressive muscle wasting disease in people older than 50 years, with no effective drug treatment. Arimoclomol is an oral co-inducer of the cellular heat shock response that was safe and well-tolerated in a pilot study of inclusion body myositis, reduced key pathological markers of inclusion body myositis in two in-vitro models representing degenerative and inflammatory components of this disease, and improved disease pathology and muscle function in mutant valosin-containing protein mice. In the current study, we aimed to assess the safety, tolerability, and efficacy of arimoclomol in people with inclusion body myositis.This multicentre, randomised, double-blind, placebo-controlled study enrolled adults in specialist neuromuscular centres in the USA (11 centres) and UK (one centre). Eligible participants had a diagnosis of inclusion body myositis fulfilling the European Neuromuscular Centre research diagnostic criteria 2011. Participants were randomised (1:1) to receive either oral arimoclomol 400 mg or matching placebo three times daily (1200 mg/day) for 20 months. The randomisation sequence was computer generated centrally using a permuted block algorithm with randomisation numbers masked to participants and trial staff, including those assessing outcomes. The primary endpoint was the change from baseline to month 20 in the Inclusion Body Myositis Functional Rating Scale (IBMFRS) total score, assessed in all randomly assigned participants, except for those who were randomised in error and did not receive any study medication, and those who did not meet inclusion criteria. Safety analyses included all randomly assigned participants who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov, number NCT02753530, and is completed.Between Aug 16, 2017 and May 22, 2019, 152 participants with inclusion body myositis were randomly assigned to arimoclomol (n=74) or placebo (n=78). One participant was randomised in error (to arimoclomol) but not treated, and another (assigned to placebo) did not meet inclusion criteria. 150 participants (114 [76%] male and 36 [24%] female) were included in the efficacy analyses, 73 in the arimoclomol group and 77 in the placebo group. 126 completed the trial on treatment (56 [77%] and 70 [90%], respectively) and the most common reason for treatment discontinuation was adverse events. At month 20, mean IBMFRS change from baseline was not statistically significantly different between arimoclomol and placebo (-3·26, 95% CI -4·15 to -2·36 in the arimoclomol group vs -2·26, -3·11 to -1·41 in the placebo group; mean difference -0·99 [95% CI -2·23 to 0·24]; p=0·12). Adverse events leading to discontinuation occurred in 13 (18%) of 73 participants in the arimoclomol group and four (5%) of 78 participants in the placebo group. Serious adverse events occurred in 11 (15%) participants in the arimoclomol group and 18 (23%) in the placebo group. Elevated transaminases three times or more of the upper limit of normal occurred in five (7%) participants in the arimoclomol group and one (1%) in the placebo group. Tubulointerstitial nephritis was observed in one (1%) participant in the arimoclomol group and none in the placebo group.Arimoclomol did not improve efficacy outcomes, relative to placebo, but had an acceptable safety profile in individuals with inclusion body myositis. This is one of the largest trials done in people with inclusion body myositis, providing data on disease progression that might be used for subsequent clinical trial design.US Food and Drug Administration Office of Orphan Products Development and Orphazyme.